cbmg_ex101




 





 Exhibit 10.1


 


Cellular
Biomedicine (Wuxi) Co., Ltd. - Basic Line of Credit -
2020042800000284

 


	

Stage:
Business application investigation


 

	

Handler:
Qian Zheng


 


	

Organization
of the handler: Renmin Zhonglu Sub-branch, Wuxi Branch


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate: Floating rate


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/28/2020, 18:08:33


 

	

Completed
at: 4/28/2020, 18:53:05


 


	

[Opinion] It is proposed to grant the basic line of credit of RMB
30 million to Cellular Biomedicine (Wuxi) Co., Ltd. for the purpose
of covering the company’s operation, maintenance and R&D
expenditures. The term of the line of credit is one year and the
loan is a working capital loan with the characteristics of interest
rate of not lower than LPR +50BP, monthly settlement, fixed
interest rate, custodian payment, and the guarantee method of
credit. Please approve.


	

[Opinion (cont.)]






 



 







 





 


	

Stage:
Branch risk manager


 

	

Handler:
Li Bo


 


	

Organization
of the handler: Wuxi Branch


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:


 


	

Business
currency:


 

	

Amount
under application (RMB): 0.00


 


	

Term
(months): 0


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/28/2020, 18:53:05


 

	

Completed
at: 4/29/2020, 10:02:36


 


	

[Opinion] The following risk control measures are recommended: 1.
Pay attention to changes in the country's macro policies and pay
close attention to the price changes of major raw materials. 2.
Strengthen credit management and pay attention to the company's
management and control in production, market, capital and other
aspects. 3. Effectively strengthen post-loan management and conduct
credit risk analysis in a timely manner to ensure the safety of the
bank's credit funds.


	

[Opinion (cont.)]






 



 







 






  


	

Stage:
Head of the Marketing Department


 

	

Handler:
Ruan Haotian


 


	

Organization
of the handler: Wuxi Branch


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/29/2020, 10:02:36


 

	

Completed
at: 4/29/2020, 15:10:40


 


	

[Opinion] Agree


	

[Opinion (cont.)]






 



 







 






 


	

Stage:
Branch analysis and evaluation (beyond the branch’s
authority)


 

	

Handler:
Xu Daoyou


 


	

Organization
of the handler: Wuxi Branch


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/29/2020, 15:21:17


 

	

Completed
at: 4/29/2020, 17:11:58


 


	

[Opinion] It is proposed to grant the basic line of credit of RMB
30 million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.


	

[Opinion (cont.)]






 



 







 






 


	

Stage:
Branch Risk Director (beyond the branch’s
authority)


 

	

Handler:
Huang Yonghong


 


	

Organization
of the handler: Wuxi Branch


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/29/2020, 17:11:58


 

	

Completed
at: 4/29/2020, 17:25:30


 


	

[Opinion] We agree to declare this.


	

[Opinion (cont.)]






 



 







 






 


	

Stage:
Branch governor (beyond the branch’s authority)


 

	

Handler:
Zhou Bo


 


	

Organization
of the handler: Wuxi Branch


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/29/2020, 17:25:30


 

	

Completed
at: 4/29/2020, 17:40:06


 


	

[Opinion] Agree


	

[Opinion (cont.)]






 



 







 






 


	

Stage:
Pre-examination at the headquarters


 

	

Handler:
Dai Jun


 


	

Organization
of the handler: Bank of Nanjing


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:
Fully authorized


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 






 



 







 






 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/30/2020, 8:40:31


 

	

Completed
at: 4/30/2020, 10:20:41


 


	

[Opinion] We agree to grant the basic line of credit of RMB 30
million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.Operations carried out with the line of credit
should be reported to the headquarters for approval.


	

[Opinion (cont.)]






 



 







 






 


	

Stage:
Countersigning stage at the headquarters


 

	

Handler:
Zhu Hua


 


	

Organization
of the handler: Bank of Nanjing


 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.


 


	

Business
type: Basic line of credit


 

	

Authorization:
Not authorized


 


	

Business
currency: RMB


 

	

Amount
under application (RMB): 30,000,000.00


 


	

Term
(months): 12


 

	

Day(s):
0


 


	

Interest
rate type:


 

	
 


	

Base
annual interest rate (%): 0.0


 

	

Floating
interest rate:


 


	

Floating
value: 0.0


 

	

Annual
interest rate (%): 0.0


 


	

Handling
fee rate (‰): 0.00


 

	

Margin
ratio (%): 0


 


	

Received
at: 4/30/2020, 10:55:19


 

	

Completed
at: 4/30/2020, 16:06:50


 


	

[Opinion] We agree to grant the basic line of credit of RMB 30
million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.Operations carried out with the line of credit
should be reported to the headquarters for approval.


	

[Opinion (cont.)]